Should you buy, sell or hold Sun Pharma shares? Here's how analysts view Q4 results
Sun Pharma share price target, Sun Pharma Q4 results, Sun Pharma share price NSE: Sun Pharmaceutical Industries shares slipped nearly five per cent on NSE to the day's low of Rs 1,467, a day after the Mumbai-headquartered firm released its March quarter results. Global brokerages have revised their targets on the stock post-earning report. Check out the latest Sun Pharma share price targets:
Sun Pharma share price today NSE
At close, Sun Pharmaceutical Industries stock fell 2.71 per cent to settle at Rs 1,497.55 on NSE.
Should you buy, sell or hold Sun Pharma stock?
CLSA has downgraded Sun Pharma to underperform from buy with a target of Rs 1,610.
Sun Pharma share price target
JP Morgan has maintained an overweight rating on Sun Pharma. The brokerage has raised the target to Rs 1,610 apiece from Rs 1,600 per share earlier.
Should you buy, sell or hold Sun Pharma shares?
Goldman Sachs has maintained a sell call on the pharma stock with a reduced target of Rs 1,270 apiece from Rs 1,275 apiece earlier.
Sun Pharma share price target
Jefferies has maintained a buy call on Sun Pharma. The brokerage has raised the target to Rs 1,785 from Rs 1,585 earlier.
Sun Pharma shares: Buy, sell or hold?
HSBC has maintained a buy call. The brokerage has trimmed the target to Rs 1,670 apiece from Rs 1,790 apiece.
Sun Pharma shares: Buy, sell or hold?
Nomura has maintained a neutral call on Sun Pharma with a target of Rs 1,444 apiece.
Sun Pharma Q4 results 2024
Sun Pharma Q4 results 2024
Sun Pharma reported a consolidated net profit of Rs 2,654.58 crore in the fourth quarter ended on March 31, 2024.
Sun Pharma Q4 revenue
Sun Pharma Q4 revenue
Consolidated total revenue from operations in the fourth quarter was at Rs 11,982.9 crore in the quarter under review. It was at Rs 10,930.67 crore in the same quarter a year ago, it added.
(Image: Pixabay and others/ Representational image)
(With PTI inputs)
(Disclaimer: The views/suggestions/advice expressed here in this article are solely by investment experts. Zee Business suggests its readers to consult with their investment advisers before making any financial decision.)